Search clinical trials for: BIA 2-093 1800 mg once daily [Group 1 (Part II)]

Total 100 results

Bial - Portela C S.A.

Completed

Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder

Bipolar I Disorder
Bial - Portela C S.A.

Completed

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Epilepsy

United States
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

Healthy
Organon and Co

Completed

A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)

Spondylitis, Ankylosing
MerLion Pharmaceuticals GmbH

Completed

Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis

Urinary Tract Infections | Acute Pyelonephritis

Germany
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Fibromyalgia
National Institute of Diabetes and Digestive and...

Completed

Improving Outcomes in Patients With Kidney Disease Due to Diabetes

Hypertension | Diabetes | Kidney Disease

United States
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
Bial - Portela C S.A.

Completed

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Partial Epilepsy

Portugal
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Extranodal NK/T-cell Lymphoma, Nasal Type

China
Federico II University

Completed

Platelet Aggregation in Diabetic Patients With Acute Coronary Syndrome Treated With Different Doses of Aspirin (DIABE-ASACS)

Diabetes Mellitus | Acute Coronary Syndrome

Italy
Virginia Commonwealth University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Interleukin-1 Blockade in Recently Decompensated Heart Failure (RED-HART)

Heart Failure

United States
University of Florida

Completed

Detecting Lung Infections Through Vibration

Lung Infection

United States
Meirav Kedmi MD
Johnson & Johnson

Unknown

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Diffuse Large B Cell Lymphoma | Recurrent Disease | Refractory Cancer | Primary Mediastinal (Thymic) Large B-cell Lymphoma | Transformed Indolent Lymphoma

Israel
Corcept Therapeutics
Gynecologic Oncology Group

Active, not recruiting

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm

United States, Argentina, Australia, Belgium, Brazil, Canada, France, Hungary, Israel, Italy, Korea, Republic of, Poland, Spain, United Kingdom
James Tarbox, MD
Texas Tech University Health Sciences Center

Recruiting

Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

Penicillin Allergy

United States
Egyptian Liver Hospital
Wadi El Nil Hospital

Completed

Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis c

Egypt
Centre Hospitalier Universitaire de Saint Etienne

Recruiting

A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty (PRADO)

Arthropathy of Hip

France
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Puerto Rico
MerLion Pharmaceuticals GmbH

Completed

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

Safety and Tolerability

United States
The George Institute
National Health and Medical Research Council, Australia

Completed

Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study (TASCS)

Chronic Obstructive Pulmonary Disease

Australia
Suzhou Zanrong Pharma Limited

Recruiting

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

Advanced Solid Tumors | HER2-positive Breast Cancer

China
Bial - Portela C S.A.

Terminated

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Epilepsy

Portugal
Dana-Farber Cancer Institute
Boston Children's Hospital

Terminated

Treatment of Childhood Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Puerto Rico, Canada
Damanhour University
Tanta University

Completed

Sacubitril/Valsartan Versus Valsartan in Heart Failure

Heart Failure

Egypt
GlaxoSmithKline
Piramal Clinical Research (Hyderabad, India)

Completed

Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions

Ulcers, Duodenal and Gastric

India
GlaxoSmithKline
Piramal Clinical Research (Hyderabad, India)

Completed

Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions

Ulcers, Duodenal and Gastric

India
Sun Yat-sen University

Recruiting

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
University of Texas Southwestern Medical Center
National Center for Research Resources (NCRR)

Completed

Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Italian Sarcoma Group
French Sarcoma Group; Grupo Espanol de Investigacion en Sarcomas

Active, not recruiting

Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults

Spain, Italy
Bayer

Completed

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Ovarian Cancer | Prostate Cancer

Italy, Belgium, Netherlands, France, Germany, United Kingdom
University Hospital Padova

Completed

MRA and ARB Treatment in Screening of Primary Aldosteronism (EMIRA)

Primary Aldosteronism Due to Aldosterone Producing Adenoma

Italy
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Small Cell Lung Cancer | Solid Tumor | Non-small Cell Lung Cancer
Mothaffar Rimawi

Terminated

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (CRIZENT)

Breast Cancer

United States
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Completed

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Head and Neck Cancer | Squamous Cell Cancer

United States
Rabin Medical Center
Tel Aviv University; The Leona M. and Harry B. Helmsley Charitable Trust

Recruiting

Biomarker-based Multidisciplinary Team (Bio-MDT) Approach to Personalized Microbial-targeted Treatment of Pouchitis and Crohn's Disease (Bio-MDT)

Inflammatory Bowel Diseases

Israel
University of Pittsburgh
Roche Pharma AG; Aventis Pharmaceuticals

Terminated

A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

Cancer

United States
Rush University Medical Center

Completed

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Nausea | Vomiting

United States
Ottawa Hospital Research Institute

Recruiting

The Influence of Concurrent Oral Calcium Carbonate Supplementation on Steady State Pharmacokinetics of Oral Raltegravir. (RCPK)

Calcium Supplementation in HIV Patients Using Raltegravir

Canada
Instituto Nacional de Cardiologia Ignacio Chavez
Boehringer Ingelheim laboratory

Not yet recruiting

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

Heart Failure | Congenital Heart Disease | Heart Failure With Reduced Ejection Fraction

Mexico
Biogen

Withdrawn

BIIB014 Phase 2a Monotherapy

Parkinson's Disease
Merck Sharp & Dohme LLC

Recruiting

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Small Cell Lung Cancer

United States, Australia, Belgium, Bulgaria, Canada, China, France, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Portugal, Romania, Russian Federation, Serbia, South Africa, Spain, Turkey, Ukraine, United... and more
M.D. Anderson Cancer Center
Assistance Publique - Hôpitaux de Paris; National Cancer Institute (NCI)

Recruiting

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

ENSAT Stage I Adrenal Cortex Carcinoma | ENSAT Stage II Adrenal Cortex Carcinoma | ENSAT Stage III Adrenal Cortex Carcinoma

United States, France, Poland
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Completed

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Follicular Lymphoma | Myeloid Leukemia | Polycythemia Vera | Hodgkin Lymphoma | Myelofibrosis | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Refractory... and other conditions

United States
Organon and Co
Quintiles, Inc.

Completed

Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500)

Seasonal Allergic Rhinitis

Search clinical trials for: BIA 2-093 1800 mg once daily [Group 1 (Part II)]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations